2015 Antineoplastics

DIFFERENTIATING AGENTS

BEXAROTENE

  • rexinoid that selectively activates retinoid X receptors, which are involved in the regulation of cell growth and differentiation

  • approved for use in patients with cutaneous T-cell lymphoma that is refractory to skin-directed treatment

  • metabolized by CYP3A4 (potential for many drug interactions)

  • side effects include: GI symptoms, lipid abnormalities and pancreatitis (must monitor blood lipid levels)

  • TERATOGENIC
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 10-may-15 8:39 PM